Announcements Trials
Browse Landscape

Status

Completed 6Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 13Head and Neck Neoplasms 9Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 3Lung Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms, Squamous Cell 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Chordoma 1Carcinoma 1Breast Neoplasms 1Advanced Cancers 1

Interventions

pembrolizumab 1Radiotherapy, Intensity-Modulated 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms, Squamous Cell × Cetuximab × Clear all
NCT01075841 2014-07-02

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Merck KGaA, Darmstadt, Germany

Withdrawn
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡